Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Retained Earnings: 2022-2025

Historic Retained Earnings for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$1.5 billion.

  • Phathom Pharmaceuticals' Retained Earnings fell 23.10% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 billion, marking a year-over-year decrease of 23.10%. This contributed to the annual value of -$1.3 billion for FY2024, which is 36.00% down from last year.
  • Phathom Pharmaceuticals' Retained Earnings amounted to -$1.5 billion in Q3 2025, which was down 2.09% from -$1.4 billion recorded in Q2 2025.
  • Phathom Pharmaceuticals' Retained Earnings' 5-year high stood at -$570.0 million during Q1 2022, with a 5-year trough of -$1.5 billion in Q3 2025.
  • Moreover, its 3-year median value for Retained Earnings was -$1.1 billion (2024), whereas its average is -$1.1 billion.
  • Data for Phathom Pharmaceuticals' Retained Earnings shows a maximum YoY slumped of 39.98% (in 2024) over the last 5 years.
  • Over the past 4 years, Phathom Pharmaceuticals' Retained Earnings (Quarterly) stood at -$727.1 million in 2022, then fell by 27.73% to -$928.7 million in 2023, then plummeted by 36.00% to -$1.3 billion in 2024, then declined by 23.10% to -$1.5 billion in 2025.
  • Its Retained Earnings stands at -$1.5 billion for Q3 2025, versus -$1.4 billion for Q2 2025 and -$1.4 billion for Q1 2025.